Jointown Pharmaceutical Group Management
Management criteria checks 3/4
Jointown Pharmaceutical Group's CEO is Yihua Gong, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.073% of the company’s shares, worth CN¥18.70M. The average tenure of the management team and the board of directors is 1.8 years and 4.5 years respectively.
Key information
Yihua Gong
Chief executive officer
CN¥825.6k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.07% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt
Mar 26
Investors Met With Slowing Returns on Capital At Jointown Pharmaceutical Group (SHSE:600998)
Feb 15Insufficient Growth At Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Hampers Share Price
Dec 31We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt
Nov 17Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss
Aug 29Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price
Aug 26These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well
Aug 01Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward
Jun 07Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors
May 21Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)
Apr 05CEO
Yihua Gong (46 yo)
Mr. Yihua Gong serves as General Manager of Jointown Pharmaceutical Group Co., Ltd. since October 15, 2024 and previously served as its General manager and also served as its Vice President. Mr. Gong has b...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & VC | less than a year | CN¥825.60k | 0.073% CN¥ 18.7m | |
| Deputy General Manager | no data | CN¥423.20k | 0.018% CN¥ 4.6m | |
| VP & Director | less than a year | CN¥603.10k | 0.0054% CN¥ 1.4m | |
| Deputy GM & Secretary of the Board of Directors | 3.1yrs | CN¥354.60k | no data | |
| Deputy General Manager | no data | CN¥1.57m | 0.0056% CN¥ 1.5m | |
| Deputy General Manager | no data | CN¥810.00k | no data | |
| Deputy General Manager | no data | CN¥382.20k | 0.00027% CN¥ 69.6k | |
| Deputy General Manager | 4.1yrs | CN¥443.40k | 0.0051% CN¥ 1.3m | |
| Deputy General Manager | no data | CN¥515.50k | no data | |
| Founder & Controller | no data | CN¥881.50k | no data | |
| Deputy General Manager | no data | CN¥441.80k | 0.014% CN¥ 3.5m | |
| Securities Affairs Representative | no data | no data | no data |
Experienced Management: 600998's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & VC | 10.5yrs | CN¥825.60k | 0.073% CN¥ 18.7m | |
| VP & Director | 3yrs | CN¥603.10k | 0.0054% CN¥ 1.4m | |
| Independent Director | no data | CN¥195.80k | no data | |
| Independent Director | no data | CN¥150.00k | no data | |
| Emeritus Vice Chairman | 1.7yrs | CN¥612.40k | 1.42% CN¥ 366.1m | |
| Vice Chairman | 10.5yrs | CN¥823.80k | 1.21% CN¥ 312.4m | |
| Director | 10.5yrs | no data | no data | |
| Chairman of Supervisory Board | 1.5yrs | CN¥722.40k | 0.0017% CN¥ 438.3k | |
| Vice Chairman | 4.5yrs | CN¥823.60k | no data | |
| Independent Director | no data | CN¥150.00k | 0.00011% CN¥ 28.4k | |
| Chairman | 4.5yrs | CN¥1.21m | no data | |
| Director | 4.5yrs | no data | no data |
Experienced Board: 600998's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 12:13 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jointown Pharmaceutical Group Co., Ltd is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaoling Wang | Chasing Securities |
| Fusheng Cheung | China Galaxy International Securities (Hong Kong) |
| Pei Cheng | China Galaxy Securities Co., Ltd. |